Lineage Cell Therapeutics (LCTX) Receivables - Net (2011 - 2026)

Lineage Cell Therapeutics has reported Receivables - Net for 16 years, with the latest figure at $806000.0 in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net rose 278.4% year-over-year to $806000.0; the trailing twelve-month figure through Mar 2026 stood at $806000.0 (up 278.4% YoY), and the FY2025 full-year result was $891000.0, up 39.66% from the prior year.
• Receivables - Net for Q1 2026 stood at $806000.0, down from $891000.0 in the prior quarter.
• The five-year high for Receivables - Net was $891000.0 in Q4 2025, with the low at $77000.0 in Q1 2024.
• Historically, Receivables - Net has averaged $410529.4 across 5 years, with a median of $405000.0 in 2024.
• The largest YoY upside for Receivables - Net was 450.63% in 2022 against a maximum downside of 99.41% in 2022.
• Lineage Cell Therapeutics' Receivables - Net stood at $300000.0 in 2022, then soared by 133.33% to $700000.0 in 2023, then fell by 8.86% to $638000.0 in 2024, then soared by 39.66% to $891000.0 in 2025, then declined by 9.54% to $806000.0 in 2026.
• The last three Receivables - Net figures came in at $806000.0 (Q1 2026), $891000.0 (Q4 2025), and $127000.0 (Q3 2025), per Business Quant data.